Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of ...

In patients with myasthenia gravis (MG) who had anti-acetylcholine receptor antibodies or anti-muscle-specific kinase ...

In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq) -- as well as three neonatal fragment ...

In today’s Health Headlines, June is Myasthenia Gravis Awareness Month. What is myasthenia gravis, how is it diagnosed, and what treatments are available?

SOURCE Myasthenia Gravis Foundation of America, Inc. The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties.

Imaavy is the first FcRn blocker approved for anti-AChR and anti-MuSK antibody positive patients with generalized myasthenia gravis.

The FDA has approved a monoclonal antibody to treat individuals aged 12 years and older with generalized myasthenia gravis who are anti-acetylcholine receptor or anti-muscle-specific kinase ...

Myasthenia gravis with double-seropositive acetylcholine receptor and low-density lipoprotein receptor-related protein 4 antibodies combined with muscle atrophy: a case report and literature review ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around.

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around.

Myasthenia gravis (MG) is an autoimmune disorder that affects how well your nerves and muscles communicate. Learn more about MG symptoms.

The FDA approved Soliris for children aged 6 and older with generalized myasthenia gravis (gMG), offering new hope for managing this autoimmune neuromuscular disorder.